Get the app today! Download iPhone App Download Android App

Takeda To Sell Japanese Consumer Health Unit To Blackstone

Published on Aug 25 2020 8:19 AM in A-Brands tagged: Japan / blackstone / Takeda / Alinamin

Takeda To Sell Japanese Consumer Health Unit To Blackstone

Takeda Pharmaceutical Co plans to it plans to sell its Japanese consumer healthcare business to U.S. buyout fund Blackstone Group.

Japan's largest pharmaceuticals company has been selling its over-the-counter (OTC) assets worldwide as it seeks to refocus its business and reduce debt following a $59 billion acquisition of Shire Plc last year.

Takeda CEO Christophe Weber said via an online briefing the company had decided to sell the Japanese OTC unit because it would be difficult for Takeda to keep investing in OTC businesses while trying to develop new drugs for more serious diseases.

"My responsibility is to make sure that we don't destroy value (for OTC businesses) but create value, and to create value we need to grow businesses and it's not good to keep business and not invest sufficiently into that," said Weber.

Sale Price

Takeda Consumer Healthcare Company, known for its Alinamin line of energy drinks, is valued at 242 billion yen (€1.93 billion) and the sale price will be determined after calculating its debt and other factors, Takeda said.

Blackstone was among the final bidders for the OTC unit, Reuters reported in June, along with Bain Capital, CVC Capital Partners and Taisho Pharmaceutical Holdings Co Ltd.

Takeda said proceeds from the sale would boost its net profit by 105 billion yen. The transaction is expected close by March 31, subject to regulatory closing conditions, it said.

News by Reuters, edited by ESM. Click subscribe to sign up to ESM: European Supermarket Magazine.

Share on Facebook Share on Twitter Share on LinkedIn Share via Email